WO2005052143A3 - Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung - Google Patents
Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung Download PDFInfo
- Publication number
- WO2005052143A3 WO2005052143A3 PCT/EP2004/012931 EP2004012931W WO2005052143A3 WO 2005052143 A3 WO2005052143 A3 WO 2005052143A3 EP 2004012931 W EP2004012931 W EP 2004012931W WO 2005052143 A3 WO2005052143 A3 WO 2005052143A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- viruses
- code
- same
- nucleic acids
- novel adenoviruses
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006538818A JP2007511212A (ja) | 2003-11-14 | 2004-11-15 | 新規アデノウイルス、それをコードする核酸及びその使用 |
US10/579,543 US20060270016A1 (en) | 2003-11-14 | 2004-11-15 | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
EP04803146.2A EP1689446B1 (de) | 2003-11-14 | 2004-11-15 | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
CA002590257A CA2590257A1 (en) | 2003-11-14 | 2004-11-15 | Novel adenoviruses, nucleic acids that code for the same and the use of said viruses |
US12/690,729 US8586354B2 (en) | 2003-11-14 | 2010-01-20 | Adenoviruses, nucleic acids that code for the same and the use of said viruses |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10353152.1 | 2003-11-14 | ||
DE10353152 | 2003-11-14 | ||
DE102004018117 | 2004-04-14 | ||
DE102004018117.9 | 2004-04-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10579543 A-371-Of-International | 2004-11-15 | ||
US12/690,729 Continuation US8586354B2 (en) | 2003-11-14 | 2010-01-20 | Adenoviruses, nucleic acids that code for the same and the use of said viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005052143A2 WO2005052143A2 (de) | 2005-06-09 |
WO2005052143A3 true WO2005052143A3 (de) | 2005-09-22 |
Family
ID=34635104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/012931 WO2005052143A2 (de) | 2003-11-14 | 2004-11-15 | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060270016A1 (de) |
EP (1) | EP1689446B1 (de) |
JP (2) | JP2007511212A (de) |
CA (1) | CA2590257A1 (de) |
WO (1) | WO2005052143A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5213298B2 (ja) | 2002-05-27 | 2013-06-19 | ホルム,ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
CN101128593B (zh) * | 2004-12-31 | 2014-09-03 | 佩尔·松内·霍尔姆 | 逆转动物细胞中多种抗性的方法 |
EP1855760A2 (de) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Kombinationstherapien mit hdac-hemmern |
PL1901729T3 (pl) * | 2005-05-13 | 2012-07-31 | Topotarget Uk Ltd | Formulacje farmaceutyczne inhibitorów hdac |
AU2006313517B2 (en) * | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
JP2009519224A (ja) * | 2005-11-18 | 2009-05-14 | グロスター ファーマシューティカルズ, インコーポレイテッド | Hdacインヒビターfk228の代謝産物誘導体 |
EP2124990A4 (de) * | 2006-12-29 | 2010-04-21 | Gloucester Pharmaceuticals Inc | Tumorbehandlung auf der basis von romidepsin |
WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
EP2203421B1 (de) * | 2007-09-25 | 2014-05-07 | TopoTarget UK Limited | Verfahren zur synthese bestimmter n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamiden verbindungen |
MX2010009642A (es) * | 2008-03-07 | 2010-09-22 | Topotarget As | Metodos de tratamiento utilizando infusion continua prolongada de belinostat. |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
ES2750305T3 (es) | 2009-03-02 | 2020-03-25 | Univ California | Mutantes de E1A y E1B de adenovirus selectivos de tumor |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
ES2965632T3 (es) * | 2018-03-05 | 2024-04-16 | Klinikum Rechts Der Isar Der Technischen Univ Muenchen | Tratamiento de tumores mediante una combinación de un adenovirus oncolítico y un inhibidor de CDK4/6 |
SG11202012978VA (en) * | 2018-06-25 | 2021-01-28 | Ospedale San Raffaele Srl | Gene therapy |
AU2020307560B2 (en) * | 2019-06-25 | 2024-03-21 | Microbiotix, Inc. | Compositions and methods of treating or preventing ocular infections with filociclovir |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020086411A1 (en) * | 1999-06-21 | 2002-07-04 | Holm Per Sonne | Agents for treating malignant diseases using the protein YB-1 |
DE10150945A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0784690B1 (de) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US20030095989A1 (en) * | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
EP1346058B1 (de) * | 2000-12-28 | 2007-05-02 | Per Sonne Holm | Adenovirale systeme und deren anwendungen |
JP5213298B2 (ja) * | 2002-05-27 | 2013-06-19 | ホルム,ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
AU2003271730A1 (en) * | 2002-10-15 | 2004-05-04 | Per Sonne Holm | Novel adenoviruses, nucleic acids coding therefor, and use thereof |
-
2004
- 2004-11-15 CA CA002590257A patent/CA2590257A1/en not_active Abandoned
- 2004-11-15 EP EP04803146.2A patent/EP1689446B1/de active Active
- 2004-11-15 WO PCT/EP2004/012931 patent/WO2005052143A2/de active Application Filing
- 2004-11-15 US US10/579,543 patent/US20060270016A1/en not_active Abandoned
- 2004-11-15 JP JP2006538818A patent/JP2007511212A/ja active Pending
-
2010
- 2010-01-20 US US12/690,729 patent/US8586354B2/en active Active
-
2011
- 2011-04-26 JP JP2011098213A patent/JP5618896B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020086411A1 (en) * | 1999-06-21 | 2002-07-04 | Holm Per Sonne | Agents for treating malignant diseases using the protein YB-1 |
DE10150945A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
Non-Patent Citations (3)
Title |
---|
FUEYO JUAN ET AL: "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo", ONCOGENE, vol. 19, no. 1, 6 January 2000 (2000-01-06), pages 2 - 12, XP002336078, ISSN: 0950-9232 * |
HOLM P S ET AL: "YB-1 relocates to the nucleus in adenovirus infected cells and facilitates viral replication E2 gene expression through the E2 late promoter", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 12, 22 March 2002 (2002-03-22), pages 10427 - 10434, XP002237181, ISSN: 0021-9258 * |
HOLM PER S ET AL: "Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: Impact for cancer gene therapy.", CANCER RESEARCH, vol. 64, no. 1, 1 January 2004 (2004-01-01), pages 322 - 328, XP002336079, ISSN: 0008-5472 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US9259452B2 (en) | 2006-06-08 | 2016-02-16 | Gelgene Corporation | Deacetylase inhibitor therapy |
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9518094B2 (en) | 2010-07-12 | 2016-12-13 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9468664B2 (en) | 2013-12-27 | 2016-10-18 | Celgene Corporation | Romidepsin formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20060270016A1 (en) | 2006-11-30 |
CA2590257A1 (en) | 2005-06-09 |
EP1689446B1 (de) | 2015-01-07 |
EP1689446A2 (de) | 2006-08-16 |
JP2011200234A (ja) | 2011-10-13 |
US8586354B2 (en) | 2013-11-19 |
US20100297731A1 (en) | 2010-11-25 |
JP2007511212A (ja) | 2007-05-10 |
WO2005052143A2 (de) | 2005-06-09 |
JP5618896B2 (ja) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005052143A3 (de) | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung | |
WO2002029056A3 (en) | Mini-dystrophin nucleic acid and peptide sequences | |
WO2005118825A3 (en) | Chimeric adenoviruses for use in cancer treatment | |
WO2003012057A3 (en) | Antisense modulation of serum amyloid a4 expression | |
AU2003225644A1 (en) | Wax ester synthase dna sequence, protein and uses thereof | |
HU0200434D0 (en) | Method to determine which requirements from a general requirements document apply to a specific situation, computer system for operating the method and computer-readable medium containing instructions for... | |
WO2007120533A3 (en) | Minigene expression cassette | |
WO2003010284A3 (en) | Antisense modulation of c-reactive protein expression | |
AU2002336768A1 (en) | Identification of modulatory molecules using inducible promoters | |
WO2002040668A3 (de) | Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen | |
WO2001077292A3 (en) | Novel signal transduction molecules | |
SG169325A1 (en) | Promoters for expression in modified vaccinia virus ankara | |
WO2006060823A3 (en) | Apoptosis-specific eif-5a and polynucleotides encoding same | |
SG165168A1 (en) | New adenoviruses, nucleic acids coding therefor and their use | |
WO2004056964A3 (en) | Vectors for inducible rna interference | |
WO2003020887A3 (en) | Gene identification | |
WO2004033706A3 (en) | Nucleic acids encoding duramycin | |
AU2003276602A1 (en) | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes | |
WO2000066743A3 (en) | Viral expression vectors | |
EP1816203A4 (de) | Für coronavirus-ähnliche partikel codierender expressionsvektor | |
WO2002053586A3 (en) | Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them | |
WO2003029409A3 (en) | Methods for generating, selecting, and identifying compounds which bind a target molecule | |
BR9911065A (pt) | Processos melhorados e materiais para transformação | |
WO2004099367A3 (en) | Methods for producing zinc finger proteins that bind to extended dna target sequences | |
WO2002103022A3 (en) | Transgenic cells expressing clucosyltransferases which glucosylate parabenzoic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006270016 Country of ref document: US Ref document number: 10579543 Country of ref document: US Ref document number: 2006538818 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004803146 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004803146 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10579543 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2590257 Country of ref document: CA |